Klkb16 Inhibitors
Chemical inhibitors of Klkb16 function through various mechanisms to reduce its activity. Aliskiren inhibits the renin enzyme, a precursor in the renin-angiotensin-aldosterone system (RAAS), thus impeding the downstream production of angiotensin I and II. Without the angiotensin II stimulus, the secretion and function of Klkb16 are diminished. Similarly, captopril and lisinopril, as ACE inhibitors, prevent the conversion of angiotensin I to angiotensin II, resulting in decreased stimulation of Klkb16. Losartan, telmisartan, valsartan, and olmesartan medoxomil operate as angiotensin II receptor blockers. By obstructing angiotensin II from engaging with its receptor, these ARBs curtail the signaling required for Klkb16's functional activity. This blockade halts the normal upregulation of Klkb16 that would occur in response to angiotensin II.
Furthermore, aldosterone has a role in regulating Klkb16, and chemicals like eplerenone, spironolactone, and canrenone target this aspect of the RAAS. Eplerenone, as a selective aldosterone receptor antagonist, and spironolactone, a non-selective antagonist, prevent aldosterone from binding to its receptor, thereby inhibiting the upregulation of Klkb16 usually stimulated by this pathway. Canrenone also belongs to this group, performing a similar function by impeding aldosterone's effect and thus indirectly reducing the activity of Klkb16. Enalapril and ramipril, like other ACE inhibitors mentioned, further contribute to the reduction of angiotensin II levels, ensuring a decrease in the regulatory influence over Klkb16. Collectively, these inhibitors act on different stages of the RAAS to ensure a comprehensive reduction in the functional activity of Klkb16.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
Captopril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is responsible for the conversion of angiotensin I to angiotensin II. By inhibiting this conversion, captopril lowers the level of angiotensin II, which is known to upregulate Klkb16. Therefore, captopril inhibits the function of Klkb16 by reducing the levels of angiotensin II. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor blocker (ARB). It prevents angiotensin II from binding to its receptor, thereby inhibiting the downstream effects, including the secretion and function of Klkb16. This results in the functional inhibition of Klkb16 due to decreased stimulation by angiotensin II. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
Eplerenone is a selective aldosterone receptor antagonist. Aldosterone can induce the expression of Klkb16. By antagonizing the aldosterone receptor, eplerenone inhibits the signal that would normally increase the functional activity of Klkb16. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone is a non-selective aldosterone receptor antagonist, which inhibits the effects of aldosterone. Since aldosterone can promote the expression of Klkb16, spironolactone indirectly inhibits the function of Klkb16 by blocking aldosterone's action. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
Telmisartan is an angiotensin II receptor blocker (ARB) with partial PPAR-gamma agonistic effects. It inhibits the action of angiotensin II on its receptor, which would otherwise contribute to the expression and function of Klkb16. Thus, telmisartan indirectly leads to the inhibition of Klkb16. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Valsartan acts as an angiotensin II receptor antagonist, blocking the effects of angiotensin II that would normally increase the expression and activity of Klkb16. This blockade results in the functional inhibition of Klkb16. | ||||||
Olmesartan Medoxomil | 144689-63-4 | sc-219482 sc-219482A | 10 mg 100 mg | $60.00 $186.00 | ||
Olmesartan medoxomil is a prodrug that, once hydrolyzed to olmesartan, acts as an angiotensin II receptor antagonist. By blocking the receptor, it inhibits the downstream signaling that would promote Klkb16 function, thus inhibiting Klkb16. | ||||||
Ramipril | 87333-19-5 | sc-205833 sc-205833A sc-205833B sc-205833C sc-205833D | 500 mg 1 g 2 g 5 g 10 g | $179.00 $245.00 $364.00 $733.00 $1254.00 | 1 | |
Ramipril is an ACE inhibitor, effectively lowering angiotensin II levels, which would otherwise enhance Klkb16 activity. The inhibition of ACE leads to decreased functional activity of Klkb16. | ||||||